Loss of PTEN and RAS activation seems comparable in their ability to increase oncogenic signalling through PI3K pathway [160], due to the coexistence of PTEN somatic mutations in melanoma harbouring BRAF mutations but not with NRAS [161]. Here, BRAF is linked to melanoma.